medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2019, Number 4

<< Back Next >>

Rev Mex Oftalmol 2019; 93 (4)

Ocular brachytherapy in the treatment of retinoblastoma. Experience in the Hospital Infantil de México

Ramírez-Patiño L, Barnoya-Pérez de EM, Lara-Molina NC, Pérez-Villanueva H, Ramírez-Ortiz MA

Language: Spanish
References: 24
Page: 194-199
PDF size: 178.58 Kb.


ABSTRACT

Objective: To describe results and complications of salvage eye treatment with brachytherapy in patients with diagnosis of bilateral retinoblastoma (Rb) and only one eye. Methods: Case series where we included all retinoblastoma patients treated with ocular brachytherapy with Iodine-125 at the Hospital Infantil de Mexico after failure of eye salvage with intravenous chemotherapy, focal transpupillary laser o transconjunctival cryotherapy and external beam radiotherapy. Results: We analyzed 7 patients, 2 females and 5 males. Two had hereditary retinoblastoma and all had bilateral disease. Mean follow-up after treatment was 5.35 years (range 3.3–11 years). Tumor control was achieved in five of seven patients; two patients undergone enucleation due to failure to achieve tumor control. One of the patients died because of secondary neoplasm. Conclusions: Ocular brachytherapy treatment in a tertiary care center offers possibilities of ocular preservation in patients with bilateral Rb and maximum oncological treatment.


REFERENCES

  1. Abramson DH, Ellsworth RM, Rozakis GW. Cryotherapy for retinoblastoma. Arch Ophthalmol. 1982;100:1253-6.

  2. Shields JA, Shields CL, Parsons H, Giblin ME. The role of photocoagulation in the management of retinoblastoma. Arch Ophthalmol. 1990;108:205-8.

  3. Murphree AL, Villablanca JG, Deegan WF, 3rd, Sato JK, Malogolowin M, Fisher A, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1348-56.

  4. Shields CL, Santos MC, Diniz W, Gunduz K, Mercado G, Cater JR, et al. Thermotherapy for retinoblastoma. Arch Ophthalmol.1999;117:885-93.

  5. Toma NM, Hungerford JL, Plowman PN, Kingston JE, Doughty D. External beam radiotherapy for retinoblastoma: II. Lens sparing technique. Br J Ophthalmol. 1995;79:112-7.

  6. Munier FL, Verwey J, Pica A, Balmer A, Zografos L, Abouzeid H, et al. New developments in external beam radiotherapy for retinoblastoma: from lens to normal tissue-sparing techniques. Clin Experiment Ophthalmol. 2008;36:78-89.

  7. Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, Beck-Popovic M. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96:1078-83.

  8. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398-404.

  9. Abramson DH, Marr BP, Brodie SE, Dunkel I, Palioura S, Gobin YP. Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: Five year review. PLoS ONE. 2012;7:e34120.

  10. Penn I. Second neoplasms following radiotherapy or chemotherapy for cancer. Am J Clin Oncol.1982;5:83-96.

  11. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573-9.

  12. Merchant TE, Gould CJ, Wilson MW, Hilton NE, Rodriguez-Galindo C, Haik BG. Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer. 2004;43:134.9.

  13. Francis JH, Barker CA, Wolden SL, McCormick B, Segal K, Cohen G, et al. Salvage/adjuvant brachytherapy after ophthalmic artery chemosurgery for intraocular retinoblastoma. Int J Radiat Oncol Biol Phys. 2013; 87:517-23.

  14. Murphree AL. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18:41-53.

  15. American Brachytherapy Society - Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13:1-14.

  16. Shields JA, Shields CL, De Potter P, Hernandez JC, Brady LW. Plaque radiotherapy for residual or recurrent retinoblastoma in 91 cases. J Pediatr Ophthalmol Strabismus. 1994;31:242-5.

  17. Singh AD, Garway-Heath D, Love S, Plowman PN, Kingston JE, Hungerford JL. Relationship of regression pattern to recurrence in retinoblastoma. Br J Ophthalmol. 1993;77:12-6.

  18. Moore RF, Stallard HB, Milner JG. Retinal Gliomata Treated by Radon Seeds. Br J Ophthalmol. 1931;15:673-96.

  19. Stallard HB. The conservative treatment of retinoblastoma. Trans Ophthalmol Soc U K. 1962;82:473-534.

  20. Shields CL, Mashayekhi A, Sun H, Uysal Y, Friere J, Komarnicky L, et al. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology. 2006;113:2087-92.

  21. Shields CL, Shields JA, Cater J, Othmane I, Singh AD, Micaily B. Plaque radiotherapy for retinoblastoma: long term tumor control and treatment complications in 208 tumors. Ophthalmology. 2001;108:2116-21.

  22. Murakami N, Suzuki S, Ito Y, Yoshimura R, Inaba K, Kuroda Y, et al.106 Ruthenium plaque therapy (RPT) for retinoblastoma. Int J Radiat Oncol Biol Phys. 2012;84:59-65.

  23. Lucas JT, McGee R, Billups CA, Qaddoumi I, Merchant TE, Brennan RC, et al. Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy in retinoblastoma. Br J Ophthalmol. 2018 Jun 28. pii: bjophthalmol-2018-311923. doi: 10.1136/bjophthalmol- 2018-311923

  24. Bellerive C, Singh AD. Radiation Retinopathy 47 Years following Brachytherapy for Retinoblastoma. Ocul Oncol Pathol. 2018;4:157-60.




2020     |     www.medigraphic.com